Taburnaemine G






Names

    • Taburnaemine G

Attributes

  • Canonical SMILES

    OC[C@@]1(C(OC)=O)[C@@](CC2=C([C@@H](C3=C4C(C(CCN([C@@H]5CO)C6[C@@]7(C(OC)=O)C[C@@]5([H])C[C@]6([H])CC)=C7N4)=CC=C3OC)C[C@]/81[H])NC9=C2C=CC=C9)([H])N(C)CC8=C\C

  • InChI

    InChI=1S/C45H56N4O7/c1-7-24-17-26-20-44(42(52)55-5)40-29(15-16-49(41(24)44)34(26)22-50)28-13-14-35(54-4)37(39(28)47-40)31-18-32-25(8-2)21-48(3)36(45(32,23-51)43(53)56-6)19-30-27-11-9-10-12-33(27)46-38(30)31/h8-14,24,26,31-32,34,36,41,46-47,50-51H,7,15-23H2,1-6H3/b25-8-/t24-,26+,31+,32+,34+,36-,41?,44+,45-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 140.35000000000002
  • #RotBonds: 7
  • MW: 764.9639999999999
  • HBD: 4
  • HBA: 9
  • logP: 5.2123000000000035
  • Chemical Formula: C45H56N4O7


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Taburnaemines A-I, Cytotoxic Vobasinyl-Iboga-Type Bisindole Alkaloids from Tabernaemontana corymbosa. J Nat Prod, 2018 (PMID 29319316).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antiproliferative

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -6.07
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney 138.51
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 18896.95
    Distribution Blood-Brain Barrier (Central Nervous System) -3.63
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.03
    Plasma Protein Binding 83.29
    Steady State Volume of Distribution 3.86
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 8.69
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -441.68
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.17
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 4.95
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -34293853.61
    Rat (Acute) 2.94
    Rat (Chronic Oral) 2.71
    Fathead Minnow 43291.03
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 3853003.68
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.9
    Log(P) 5.0
    Log S -5.45
    Log(Vapor Pressure) -126796.32
    Melting Point 271.89
    pKa Acid -871.29
    pKa Basic 6.93